Compound Radar

Crinetics Pharmaceuticals Inc (CRNX) Stock Analysis

United States · Healthcare / Biotechnology

Price $84.95
Market cap $9.01B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

59
59/100 Acceptable
  • Financial Health 70
  • Profitability 55
  • Business Quality 50
  • Balance Sheet 65
  • Cash Flow 60

Why this rating?

Health 59/100 — Acceptable

Strongest Financial Health 70/100
Softest Business Quality 50/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Crinetics Pharmaceuticals Inc (CRNX) is a Biotechnology company in the Healthcare sector. Compound Radar rates Crinetics Pharmaceuticals Inc 59/100 (Acceptable) due to solid business quality and strong revenue growth.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Unknown

Financial highlights

Valuation

  • Forward P/E -21.17
  • EV/Revenue 186.25

Profitability

  • Revenue Growth 2336.3%
  • Gross Margin 0.0%
  • Operating Margin -527.3%
  • Net Margin 0.0%
  • ROE -42.4%

Financial strength

  • Cash $1.21B
  • Debt $47.19M
  • Net Cash $1.16B
  • Free Cash Flow $-383.68M
  • Current Ratio 15.57

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Crinetics Pharmaceuticals Inc (CRNX).

View Methodology & FAQ →